|Bid||0.00 x 4000|
|Ask||0.00 x 800|
|Day's Range||28.50 - 29.39|
|52 Week Range||28.50 - 47.82|
|Beta (3Y Monthly)||1.38|
|PE Ratio (TTM)||27.51|
|Earnings Date||Feb 26, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.63|
Mesalamine Delayed-Release Tablets help individuals manage their ulcerative colitis. HERTFORDSHIRE, England and PITTSBURGH , Dec. 17, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: ...
Mylan's Mesalamine Rectal Suppository treats mildly to moderately active ulcerative proctitis The company is awarded 180 days of marketing exclusivity HERTFORDSHIRE, England and PITTSBURGH , Dec. 17, 2018 ...
The last few years for drug-maker Teva Pharmaceuticals (NASDAQ:TEVA) haven’t exactly been that wonderful. TEVA stock has plunged on a series of mishaps and issues. In fact, TEVA has fallen enough that America’s favorite value investor, Warren Buffett, has taken a huge interest in the stock over the last few quarters.
Sanofi is heavily reliant on Lantus, its leading product with sales of 4.62 billion euros ($5.26 billion) in 2017, and Mylan's own insulin drug would be its second competitor after Eli Lilly launched its version in late 2016. Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and paediatric patients with type 1 diabetes to control high blood sugar. Sanofi, which settled a similar case with Lilly in 2016, allowing it to launch Basaglar, sued Mylan in October 2017.
U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is heavily reliant on Lantus, its leading product with sales of 4.62 billion euros ($5.26 billion) in 2017, and Mylan's own insulin drug would be its second competitor after Eli Lilly launched its version in late 2016. Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and paediatric patients with type 1 diabetes to control high blood sugar.
Mylan N.V. said on Thursday the U.S. Patent and Trademark Office invalidated French drug company Sanofi's formulation patents on its blockbuster insulin drug Lantus, ruling in favor of the U.S. drugmaker. ...
HERTFORDSHIRE, England and PITTSBURGH, Dec. 13, 2018 /PRNewswire/ -- Mylan N.V. (MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in its inter partes review (IPR) proceedings and found all claims of Sanofi's Lantus (insulin glargine 100 Units/mL) formulation patents (U.S. Patent Nos.
Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.
The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.
TRENTON, N.J. (AP) — In a story Dec. 6 about a new alternative to EpiPen, The Associated Press reported erroneously that emergency allergy injector Auvi-Q was among products that had shortages because of an EpiPen shortage. Auvi-Q did not have shortages.
Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year.
Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products. Sandoz will start selling the pre-filled epinephrine syringes, SYMJEPI, in the United States in the first quarter of 2019 at a wholesale price of $250 for a two-pack of 0.3 mg injections, Novartis said in a statement.
On December 5, Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, announced that the US FDA provided 510(K) clearance for its Ultra multifocal contact lenses for use in patients with astigmatism. The Ultra multifocal toric lens will be the first of its kind available for standard use.
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
Mylan NV said on Tuesday it is expanding a nationwide voluntary recall of its blood pressure medicine valsartan to include all lots, two weeks after it recalled select batches. Several drugmakers, including Teva Pharmaceutical Industries Ltd, have recalled batches of valsartan and drugs containing the substance that are suspected to be tainted with probable carcinogens N-nitrosodiethylamine (NDEA)and N-nitrosodimethylamine (NDMA). Global health authorities have also clamped down, with European regulators last month effectively banning sales of the product, made by Mylan's India-based unit, in Europe.
HERTFORDSHIRE, England and PITTSBURGH , Dec. 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary ...
Mylan's Lansoprazole Delayed-Release Orally Disintegrating Tablets are approved to treat certain types of gastrointestinal ulcers HERTFORDSHIRE, England and PITTSBURGH , Dec. 4, 2018 /PRNewswire/ -- Global ...